as learning disability) in Kent we have just completed a quality improvement project on attitudes towards video consultations among the staff in care settings.

We found that the majority of the care staff interviewed felt that video consultations would not have a negative impact on access to (67%) or on the quality of care (69%) provided by our mental health service for people with intellectual disability. Additionally, we asked care staff if they would consider using video consultations in place of face-to-face consultations beyond the time frame of the coronavirus disease 2019 (COVID-19) pandemic. Again, we found that the majority (66.7%) said they would.

Around a third of care staff stated that video consultations could be a good alternative to face-to-face appointments as they would allow them to still go ahead even if the service users declined to leave their accommodation. Other care staff explained that video consultations would allow clinicians to see the service users in their own environment and that they may make it easier to involve multiple healthcare professionals in an appointment. The most frequently cited benefit of video consultations was the potential to alleviate the worry and anxiety that some service users experience when going to a clinic appointment.

The attitudes towards video consultations among care staff were overall positive but they were not uniformly so. For example, it was mentioned that having a video consultation may mean that the service user is more likely to become distracted. Another respondent mentioned that for their service users, much of the information needed is derived from non-verbal communication and observed behaviour, which may be more difficult to assess over video. One carer stated that it would be too difficult to get their service user to cooperate with using the communication device.

These findings may be of particular significance in the world we face post-COVID-19 lock-down where individuals may experience increased anxiety associated with healthcare settings. The month of April 2020 saw a 48% fall in attendances to accident and emergency departments when compared with the previous year, and the fall was 72% for minor conditions such as obesity, hypertension, diabetes, cardiovascular disease, or chronic respiratory disease; and those who smoke. People with SMD already have a 2–3 times higher premature mortality rate, accounting for a 10–20-year reduction in life expectancy, mediated through increased exposure to risk factors for non-communicable diseases, such as smoking, harmful use of alcohol, sedentary behaviour, iatrogenic effects of medications and inequitable access to healthcare services. Those with SMD also often receive poor quality care, including health promotion and prevention, screening and treatment.

Individuals at higher risk for severe COVID-19 infection and mortality are people aged over 60; with underlying conditions such as obesity, hypertension, diabetes, cardiovascular disease, or chronic respiratory disease; and those who smoke. For other infectious diseases, people with SMD are likely to be at increased risk of: (a) exposure to the disease; (b) accessing less effective healthcare; and (c) increased vulnerability for significant morbidity and mortality.

Although there are overlaps with pre-existing multilevel risk factors, there are some important differences. For individuals with SMD, disorder-specific factors of COVID-19 such as early symptoms being common and non-specific could delay diagnosis, and it is possible that people with SMD may be less able to self-monitor and raise concerns if their condition deteriorates. Furthermore, COVID-19 has the potential to mimic signs and symptoms seen in severe clozapine-associated complications, such as neutropenic sepsis and myocarditis, which can be difficult to diagnose and treat. For individuals with SMD, the risk of COVID-19 infection is increased and the risk of complications and mortality is higher, especially in those with underlying medical conditions.

Individual vulnerabilities are exacerbated by health system factors such as absence of relevant shared guidelines for the management of COVID-19 from physical health and mental health bodies, diversion of resources from mental health
settings, high rates of COVID-19 illness within the health workforce, and the challenges of infection control management in mental healthcare settings, exacerbated by global shortages of personal protective equipment (PPE).

People with SMD have continued higher exposure to sociocultural risk factors including experiences of stigma and discrimination, living in deprived neighbourhoods, and limited family and community resources. At present the impact of these factors within the context of the COVID-19 pandemic is unclear.

We suggest the following measures to address individual, facility and health system determinants of health.

Individuals should be supported with infection prevention, for example the direct provision of education about hand-washing, social distancing and the signs and symptoms of COVID-19 along with health promotion strategies such as smoking cessation or harm reduction, reducing drug and alcohol use, and optimising conditions such as diabetes mellitus, chronic respiratory conditions and cardiovascular health. People with SMD should maintain contact with mental healthcare teams and receive ongoing review of mental health needs. At present although there has been some specific guidance on supporting people with cognitive impairment and dementia, it remains unclear what the impact of the pandemic may be on people with SMD, a group who may be especially vulnerable because of pre-existing social isolation, which may be further exacerbated by social distancing measures.

Staff at mental health community and residential facilities should have equal access to PPE and training on infection control in order to reduce the risks of infection. Urgent reviews of visitor policies, and assurance of sick pay for self-isolating staff are also needed.

Further consideration is needed to optimise effective delivery of care when mental and physical health staff reduce routine face-to-face meetings, and to minimise disruptions in the supply of medication and routine monitoring of medications such as clozapine and lithium. People with SMD may need additional support in accessing services when community health centre staff adopt new ways of working, such as telephone or video consultations.

People with SMD should be offered the same level of treatment for physical healthcare in line with the principles of non-discrimination, the Right to Health, and the fundamental demand of the United Nations Sustainable Development Goals, namely to ‘leave no-one behind’.

Shuo Zhang, CT2, South London and Maudsley NHS Foundation Trust, UK; email: Shuo.zhang@kcl.ac.uk; Jayati Das-Munshi, Consultant Psychiatrist and Clinician Scientist Fellow, Department of Psychological Medicine, IOPPP, King’s College London, UK; Graham Thornicroft, Professor of Community Psychiatry, Centre for Global Mental Health and Centre for Implementation Science, IOPPP, King’s College London, UK.

Declaration of interest

None.


doi:10.1192/bjb.2020.92 © The Authors 2020. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Obituaries

Freda E. Martin, MD, FRCPsych, FRCPsych (Canada)
Formerly Chair, Department for Children and Parents, Tavistock Clinic, London, and Executive Director, CM Hincks Treatment Centre, Toronto, Canada

Freda Martin, who died in Toronto on 2 August 2019 at the age of 87, was one of the early pioneers of family therapy, first in the UK and then in Canada. In 1962, while working at the...